Stocklytics Platform
Asset logo for symbol ACLX
Arcellx
ACLX56
$65.85arrow_drop_down1.09%-$0.72
Asset logo for symbol ACLX
ACLX56

$65.85

arrow_drop_down1.09%
Key Stats
Open$66.17
Prev. Close$66.57
EPS-0.71
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range63.86
66.89
52 Week Range30.88
111.51
Ratios
EPS-0.71
Fundamentals
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ACLX-
US Healthcare Sector-
US Market-
warning

ACLX / Market

ACLX lose to the US Market which returned -1.04% over the last twenty four hours.
warning

ACLX / Healthcare Sector

ACLX lose to the US Healthcare sector which returned 1.85% over the last twenty four hours.

Arcellx (ACLX) Statistics

Arcellx, Inc. (ACLX) is a biotechnology company that is focused on developing and commercializing novel cell therapies for the treatment of cancer. The company's proprietary platform, known as Alpha-1, is designed to harness the power of the immune system to target and eliminate cancer cells. With a deep understanding of T cell biology and cancer immunology, Arcellx is able to engineer T cells that are capable of recognizing and killing cancer cells with high precision and potency.
In terms of stock statistics, Arcellx, Inc. (ACLX) is listed on the NASDAQ exchange under the ticker symbol ACLX. As of the latest available data, the stock has a market capitalization of XYZ and a price-to-earnings ratio of ABC. These valuation metrics suggest that the market has assigned a certain value to Arcellx, Inc. based on its financial performance and growth prospects. Investors often use these metrics to assess the relative value of a stock compared to its peers in the sector.
add Arcellx to watchlist

Keep an eye on Arcellx

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Arcellx (ACLX) stock's performance compared to its sector and the market over the past year?

Over the past year, Arcellx (ACLX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.95%, Arcellx has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 48.42%, it has fallen short of the market average. This comparison highlights Arcellx's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Arcellx (ACLX) stock?

The PE ratio for Arcellx (ACLX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Arcellx (ACLX) stock?

The Earnings Per Share (EPS) for Arcellx (ACLX), calculated on a diluted basis, is -$0.71. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Arcellx (ACLX) stock?

The operating margin for Arcellx (ACLX) is -129.14%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Arcellx (ACLX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Arcellx (ACLX) is -$65.3M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Arcellx (ACLX) have?

Arcellx (ACLX) has a total debt of $65.33M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$96.51M.

Take Your Investments to a Whole New Level